JO3002B1 - مركبات و تركيبات كمثبطات كيناز بروتين - Google Patents

مركبات و تركيبات كمثبطات كيناز بروتين

Info

Publication number
JO3002B1
JO3002B1 JOP/2010/0297A JOP20100297A JO3002B1 JO 3002 B1 JO3002 B1 JO 3002B1 JO P20100297 A JOP20100297 A JO P20100297A JO 3002 B1 JO3002 B1 JO 3002B1
Authority
JO
Jordan
Prior art keywords
protein kinase
kinase inhibitors
abnormal
compounds
diseases
Prior art date
Application number
JOP/2010/0297A
Other languages
Arabic (ar)
English (en)
Inventor
Tellew John
Poon Daniel
Wang Xing
Jin Xianming
Liu Zuosheng
Haung Shenlin
Wan Yongqin
Xie Yongping
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42782253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3002(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Application granted granted Critical
Publication of JO3002B1 publication Critical patent/JO3002B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JOP/2010/0297A 2009-08-28 2010-08-26 مركبات و تركيبات كمثبطات كيناز بروتين JO3002B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23807309P 2009-08-28 2009-08-28
US31303910P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
JO3002B1 true JO3002B1 (ar) 2016-09-05

Family

ID=42782253

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0297A JO3002B1 (ar) 2009-08-28 2010-08-26 مركبات و تركيبات كمثبطات كيناز بروتين

Country Status (49)

Country Link
US (12) US8501758B2 (h)
EP (2) EP2470526B1 (h)
JP (2) JP5475888B2 (h)
KR (1) KR101413392B1 (h)
CN (2) CN102725283B (h)
AR (1) AR077975A1 (h)
AU (1) AU2010286569C1 (h)
BR (1) BR112012004453B1 (h)
CA (1) CA2771775C (h)
CL (1) CL2012000340A1 (h)
CO (1) CO6612222A2 (h)
CR (1) CR20120102A (h)
CU (1) CU24110B1 (h)
CY (3) CY1118452T1 (h)
DK (2) DK2470526T3 (h)
DO (1) DOP2012000051A (h)
EA (2) EA025222B1 (h)
EC (2) ECSP12011700A (h)
ES (2) ES2610825T3 (h)
GE (1) GEP20146102B (h)
GT (1) GT201200053A (h)
HN (1) HN2012000441A (h)
HR (2) HRP20140799T1 (h)
HU (3) HUE032847T2 (h)
IL (1) IL218084A (h)
IN (1) IN2012DN02469A (h)
JO (1) JO3002B1 (h)
LT (3) LT2727918T (h)
LU (2) LUC00102I2 (h)
MA (1) MA33604B1 (h)
ME (2) ME02684B (h)
MX (1) MX2012002546A (h)
MY (1) MY156259A (h)
NI (1) NI201200029A (h)
NL (1) NL300973I2 (h)
NO (2) NO2019011I1 (h)
NZ (1) NZ598924A (h)
PE (1) PE20120861A1 (h)
PL (2) PL2470526T3 (h)
PT (2) PT2727918T (h)
RS (2) RS53489B1 (h)
SG (2) SG178351A1 (h)
SI (2) SI2470526T1 (h)
SM (3) SMT201700036T1 (h)
TN (1) TN2012000081A1 (h)
UA (1) UA112285C2 (h)
UY (1) UY32860A (h)
WO (1) WO2011025927A1 (h)
ZA (1) ZA201202020B (h)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CA2789696C (en) 2010-02-25 2017-11-07 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US8907270B2 (en) 2010-06-30 2014-12-09 Schlumberger Technology Corporation Method and apparatus for gain regulation in a gamma detector
MX354725B (es) 2011-11-11 2018-03-16 Novartis Ag Metodo de tratamiento de una enfermedad proliferativa.
UA115039C2 (uk) * 2011-11-23 2017-09-11 Еррей Біофарма Інк. Фармацевтичні композиції
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
UY34540A (es) * 2011-12-23 2013-06-28 Millennium Pharm Inc Heteroarilos y usos de los mismos
EP3333575B1 (en) 2012-03-28 2020-02-26 Dana Farber Cancer Institute, Inc. C-raf mutants that confer resistance to raf inhibitors
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
CA2878469A1 (en) 2012-07-18 2014-01-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
PT2882440T (pt) * 2012-08-07 2019-04-23 Array Biopharma Inc Combinações farmacêuticas compreendendo um inibidor de braf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa
US11087354B2 (en) 2012-08-17 2021-08-10 Genentech, Inc. Combination therapies
WO2014047330A1 (en) * 2012-09-19 2014-03-27 Jean-Michel Vernier Novel raf kinase inhibitors
EP2916834A1 (en) 2012-11-08 2015-09-16 Novartis AG Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
UA118846C2 (uk) 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
US9873700B2 (en) 2013-05-30 2018-01-23 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
AU2014368906B2 (en) * 2013-12-20 2020-04-30 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of ERK and RAF inhibitors
BR112016012506A8 (pt) * 2013-12-23 2018-01-30 Novartis Ag combinações farmacêuticas, seus usos, e uso de um portador de dados
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
DE102015103158A1 (de) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Verbindungen für die Behandlung des Melanoms
JP6576962B2 (ja) 2014-03-14 2019-09-18 ノバルティス アーゲー Lag−3に対する抗体分子およびその使用
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
WO2015175846A2 (en) * 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2016038582A1 (en) * 2014-09-12 2016-03-17 Novartis Ag Compounds and compositions as raf kinase inhibitors
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
CN107106687A (zh) 2014-10-03 2017-08-29 诺华股份有限公司 组合治疗
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
BR112017018908A2 (pt) 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
JP2019500355A (ja) 2015-12-30 2019-01-10 セントルイス ユニバーシティ 汎インテグリンアンタゴニストとしてのメタ−アザ環式アミノ安息香酸誘導体
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
CA3026361A1 (en) * 2016-06-03 2017-12-07 Giordano Caponigro Pharmaceutical combinations
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CA3048376A1 (en) * 2016-12-27 2018-07-05 Riken Bmp-signal-inhibiting compound
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107540699A (zh) * 2017-10-16 2018-01-05 康化(上海)新药研发有限公司 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
JP7262843B2 (ja) * 2018-07-12 2023-04-24 深▲チェン▼市塔吉瑞生物医薬有限公司 ジアリールピラゾール化合物、該化合物を含む組成物およびその使用
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
US20220168250A1 (en) 2019-05-16 2022-06-02 Eli Lilly And Company TRIPLE COMBINATION OF AN ERK1/2 INHIBITOR WITH A BRAF INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF BRAFv6ooE COLORECTAL CANCER
EP4069692A1 (en) 2019-12-05 2022-10-12 Institut National de la Santé et de la Recherche Médicale (INSERM) N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenyl)sulfonamide compounds and their uses as braf inhibitors
TW202426436A (zh) 2020-06-09 2024-07-01 美商艾瑞生藥股份有限公司 用於治療braf相關的疾病和病症之化合物
US20230303551A1 (en) 2020-08-13 2023-09-28 Albert Einstein College Of Medicine N-cyclyl-sulfonamides useful for inhibiting raf
EP4225307A1 (en) 2020-10-05 2023-08-16 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
TW202313046A (zh) 2021-06-09 2023-04-01 瑞士商赫孚孟拉羅股份公司 用於癌症治療之組合療法
CN114181197B (zh) * 2022-02-16 2022-05-06 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024163166A1 (en) * 2023-01-30 2024-08-08 5Metis, Inc. Boron containing compounds and their uses
CN116396222A (zh) * 2023-04-10 2023-07-07 上海睿腾医药科技有限公司 一种康奈非尼中间体1-(3-氨基-1-异丙基-1h-吡唑-4-基)乙-1-酮的合成方法
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104250A (en) * 1976-08-11 1978-08-01 Borg-Warner Corporation Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
EP0184384B1 (en) 1984-12-06 1989-08-02 Pfizer Inc. Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
WO1997008950A1 (en) 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AU728701B2 (en) 1996-05-23 2001-01-18 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of Raf-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU754830C (en) 1997-05-22 2004-02-12 G.D. Searle Llc Substituted pyrazoles as p38 kinase inhibitors
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
AU782469B2 (en) 1999-12-23 2005-08-04 Mayne Pharma International Pty Ltd Improved pharmaceutical compositions for poorly soluble drugs
WO2002018654A1 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
RU2333754C2 (ru) 2001-10-25 2008-09-20 Новартис Аг Композиции, содержащие избирательный ингибитор циклооксигеназы-2
EP1456180B1 (en) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
TWI338685B (en) 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
CA2537991A1 (en) 2003-09-23 2005-03-31 Novartis Ag Combination of a vegf receptor inhibitor with a chemotherapeutic agent
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
EP1706400A1 (en) 2004-01-09 2006-10-04 Novartis AG Phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl -amine derivatives as igf-ir inhibitors
CA2567662C (en) 2004-06-10 2012-11-27 Irm Llc Compounds and compositions as protein kinase inhibitors
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
CA2601766A1 (en) 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
US20070099856A1 (en) 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
AU2006279794B2 (en) 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
BRPI0614870A2 (pt) 2005-08-22 2011-04-19 Novartis Ag composições farmacêuticas
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
WO2007105058A2 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
MX2008012716A (es) 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
AU2007296744A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
AU2007305016B2 (en) 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN101522026A (zh) * 2006-10-06 2009-09-02 Irm责任有限公司 蛋白激酶抑制剂及其应用方法
AR065335A1 (es) 2007-02-15 2009-06-03 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
BRPI0815042A2 (pt) * 2007-08-01 2015-02-10 Pfizer Compostos de pirazol
KR20100087170A (ko) 2007-10-19 2010-08-03 애보트 게엠베하 운트 콤파니 카게 N-아릴 우레아계 약물의 고체 분산액 생성물
WO2009062676A2 (en) * 2007-11-14 2009-05-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5384611B2 (ja) 2008-03-21 2014-01-08 ノバルティス アーゲー 新規ヘテロ環式化合物およびそれらの使用
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PT2324008E (pt) * 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
CN102123987A (zh) 2008-07-28 2011-07-13 吉里德科学公司 亚环烷基和亚杂环烷基组蛋白脱乙酰酶抑制剂化合物
TW201018670A (en) 2008-09-29 2010-05-16 Boehringer Ingelheim Int New chemical compounds
EA020783B1 (ru) 2008-10-07 2015-01-30 Астразенека Юк Лимитед Фармацевтическая композиция, содержащая 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-он и коповидон
WO2010056662A1 (en) * 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
EP2373664B1 (en) 2008-12-19 2013-06-12 Nerviano Medical Sciences S.r.l. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
US8546413B2 (en) * 2009-06-15 2013-10-01 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) * 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN102947290B (zh) 2010-01-27 2015-05-27 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
BR112013023970B1 (pt) 2011-03-21 2021-11-16 Valcuria Ab Uso de uma combinação de ácido valproico ou um sal farmaceuticamente aceitável deste e prednisona ou dexametasona ou um sal farmaceuticamente aceitável deste
JP6200884B2 (ja) 2011-06-14 2017-09-20 ノバルティス アーゲー 骨髄増殖性腫瘍などの癌の治療におけるパノビノスタットおよびルキソリチニブの組合せ
MX354725B (es) 2011-11-11 2018-03-16 Novartis Ag Metodo de tratamiento de una enfermedad proliferativa.
UA115039C2 (uk) 2011-11-23 2017-09-11 Еррей Біофарма Інк. Фармацевтичні композиції
EP2916834A1 (en) 2012-11-08 2015-09-16 Novartis AG Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
US10576680B2 (en) 2015-11-19 2020-03-03 The Boeing Company Modular thermoforming system

Also Published As

Publication number Publication date
US8501758B2 (en) 2013-08-06
DK2727918T3 (da) 2017-01-23
EP2727918A1 (en) 2014-05-07
CN103896921A (zh) 2014-07-02
ECSP23004573A (es) 2023-04-28
NL300973I2 (nl) 2022-05-05
US10005761B2 (en) 2018-06-26
US10568884B2 (en) 2020-02-25
BR112012004453A8 (pt) 2021-06-08
NO2019012I1 (no) 2019-03-05
JP6045519B2 (ja) 2016-12-14
CL2012000340A1 (es) 2012-08-17
AU2010286569A1 (en) 2012-04-12
HN2012000441A (es) 2015-01-05
HRP20140799T1 (hr) 2014-11-07
SG178351A1 (en) 2012-03-29
GEP20146102B (en) 2014-05-27
US20160263113A1 (en) 2016-09-15
US9593099B2 (en) 2017-03-14
HUS1900013I1 (hu) 2019-04-29
US20230116233A1 (en) 2023-04-13
IL218084A0 (en) 2012-04-30
NI201200029A (es) 2012-05-29
KR101413392B1 (ko) 2014-06-27
PT2727918T (pt) 2017-01-20
LT2727918T (lt) 2017-01-25
LTC2470526I2 (lt) 2020-04-27
CA2771775A1 (en) 2011-03-03
ZA201202020B (en) 2012-12-27
US20110306625A1 (en) 2011-12-15
NL300973I1 (h) 2019-03-27
US20160120866A1 (en) 2016-05-05
IN2012DN02469A (h) 2015-08-21
BR112012004453A2 (pt) 2021-03-09
LTPA2019005I1 (lt) 2019-03-25
CY2019013I2 (el) 2019-11-27
USRE49556E1 (en) 2023-06-20
JP2014098022A (ja) 2014-05-29
MY156259A (en) 2016-01-29
CN102725283B (zh) 2014-02-26
CN102725283A (zh) 2012-10-10
UY32860A (es) 2011-03-31
WO2011025927A1 (en) 2011-03-03
DK2470526T3 (da) 2014-08-25
US20160280686A1 (en) 2016-09-29
MA33604B1 (fr) 2012-09-01
EP2470526B1 (en) 2014-05-28
SI2470526T1 (sl) 2014-09-30
CY2019013I1 (el) 2019-11-27
JP5475888B2 (ja) 2014-04-16
TN2012000081A1 (en) 2013-09-19
EA201500175A1 (ru) 2015-05-29
SMT201700036B (it) 2017-03-08
HUE032847T2 (hu) 2017-11-28
JP2013503186A (ja) 2013-01-31
HK1167390A1 (en) 2012-11-30
US20130296318A1 (en) 2013-11-07
KR20120062839A (ko) 2012-06-14
PL2470526T3 (pl) 2014-10-31
RS55568B1 (sr) 2017-05-31
US20200323852A1 (en) 2020-10-15
HRP20170005T1 (hr) 2017-03-10
EA201200373A1 (ru) 2012-09-28
CO6612222A2 (es) 2013-02-01
US20180297985A1 (en) 2018-10-18
ES2492499T3 (es) 2014-09-09
AR077975A1 (es) 2011-10-05
LUC00101I2 (h) 2020-01-23
AU2010286569B2 (en) 2013-10-10
LUC00102I2 (h) 2024-05-21
SMT201400133B (it) 2014-11-10
CY1118452T1 (el) 2017-07-12
CU24110B1 (es) 2015-07-30
SMT201700036T1 (it) 2017-03-08
US9850230B2 (en) 2017-12-26
SI2727918T1 (sl) 2017-02-28
LTPA2019006I1 (lt) 2019-03-25
CN103896921B (zh) 2016-02-24
US20160122324A1 (en) 2016-05-05
RS53489B1 (en) 2015-02-27
CR20120102A (es) 2012-05-02
EP2470526A1 (en) 2012-07-04
SG10201405311TA (en) 2014-09-26
ME01860B (me) 2014-12-20
US9850229B2 (en) 2017-12-26
CY2019014I1 (el) 2019-11-27
EA025222B1 (ru) 2016-12-30
MX2012002546A (es) 2012-04-11
PL2727918T3 (pl) 2017-06-30
US20180297986A1 (en) 2018-10-18
US20160280687A1 (en) 2016-09-29
LUC00101I1 (h) 2019-02-13
CY2019014I2 (el) 2019-11-27
NO2019011I1 (no) 2019-03-05
CA2771775C (en) 2015-01-20
CU20120034A7 (es) 2012-06-21
US10576080B2 (en) 2020-03-03
PE20120861A1 (es) 2012-07-14
DOP2012000051A (es) 2012-05-31
HUS1900012I1 (hu) 2019-04-29
ECSP12011700A (es) 2012-03-30
GT201200053A (es) 2014-03-27
ES2610825T3 (es) 2017-05-03
US9593100B2 (en) 2017-03-14
BR112012004453B1 (pt) 2022-04-26
ME02684B (me) 2017-06-20
AU2010286569C1 (en) 2019-11-28
PT2470526E (pt) 2014-09-01
US9314464B2 (en) 2016-04-19
IL218084A (en) 2016-11-30
EP2727918B1 (en) 2016-10-12
NZ598924A (en) 2013-07-26
UA112285C2 (uk) 2016-08-25

Similar Documents

Publication Publication Date Title
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
PH12014500351B1 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
MX343534B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
IN2012DN02471A (h)
PH12014500468A1 (en) Heterocyclic compounds and uses thereof
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
BR112013033098B8 (pt) inibidores de glicosidade seletivos e usos dos mesmos
EA200901484A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
PH12012502070A1 (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
PH12012501389A1 (en) Hedgehog inhibitors
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
UA105483C2 (uk) Похідні ізохінолінону, композиція на їх основі та застосування як інгібіторів рі3k